- Work +1 202 626 3600
- Fax +1 202 639 9355
- Work 1 202 626 3609
Antitrust, Commercial Litigation, Pharmaceuticals and Healthcare
Full lawyer profile available at whitecase.com/mgidley
United States: Antitrust
White & Case LLP’s antitrust department has been extremely busy in cartel-related work, an area where it enjoys a very good reputation. ‘It is difficult to receive better service’ said one client; the lawyers have ‘extensive trial experience, don’t let balls drop and communicate extremely well’. Following a seven-year, multi-jurisdictional grand jury investigation into the firm’s client, Nexans, a manufacturer of copper and optical fiber cable products, the DOJ’s Antitrust Division finally admitted defeat. Another key client is Toshiba, which the firm represented in multiple cases related to cathode ray tubes (CRT) and lithium-ion batteries. The department, which is headed by Mark Gidley, also acted for clients in investigations into the autoparts, capacitors, chemical and hi-tech industries. Martin Toto in New York has ‘an excellent feel for arguments that will work before a jury’, and Christopher Curran’s ‘cross-examinations are brilliant’.
Civil litigation/class actions
Within: Civil litigation/class actions
White & Case LLP has ‘extensive trial experience’ and is noted for its string of major litigation successes against plaintiffs and US competition authorities. A recent such highlight was defending Toshiba against price-fixing claims brought by Motorola relating to the purchase of LCD panels; Christopher Curran (‘able to impartially assess the strengths and weaknesses of a case as a jury would see them’) and Martin Toto (‘capable of making an experienced opposing expert look ridiculous in cross-examination’) were part of a cross-office team that obtained the dismissal of all of Motorola’s claims following a Supreme Court decision to deny Motorola’s request for certiorari. The practice, headed by Mark Gidley, features prominently in pharmaceutical antitrust disputes and recent clients include Warner Chilcott, Novartis and Pfizer.